Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
This study has been terminated.
(Limited efficacy response observed during interim analysis.)
Sponsor:
Infinity Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Infinity Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00817362
First received: January 5, 2009
Last updated: December 7, 2012
Last verified: December 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been terminated. |
|---|---|
| Study Completion Date: | May 2011 |
| Primary Completion Date: | August 2010 (Final data collection date for primary outcome measure) |
| Certification or Request for Extension to Delay Results Received: | December 6, 2012 |